Our findings not only provide a novel mechanism of p53 inactivation in HCC cells but also demonstrate the crucial role of MCB1 in HCC development, which suggests that targeting MCB1 could be a novel therapeutic strategy for HCC patients. This evidence concerns the gene PSMD4 and hepatocellular carcinoma.